| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5643602 | PADAGIS US | Oral composition for the treatment of inflammatory bowel disease |
Jul, 2014
(9 years ago) | |
|
US5643602 (Pediatric) | PADAGIS US | Oral composition for the treatment of inflammatory bowel disease |
Jan, 2015
(9 years ago) | |
Entocort Ec is owned by Padagis Us.
Entocort Ec contains Budesonide.
Entocort Ec has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Entocort Ec are:
- US5643602
- US5643602*PED
Entocort Ec was authorised for market use on 02 October, 2001.
Entocort Ec is available in capsule, delayed release;oral dosage forms.
Entocort Ec can be used as treatment of mild to moderate active chrohn's disease involving the ileum and/or the ascending colon and the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum and/or ascending colon for up to 3 months.
The generics of Entocort Ec are possible to be released after 29 April, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 29, 2019 |
| M(M-178) | Apr 29, 2019 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 02 October, 2001
Treatment: Treatment of mild to moderate active chrohn's disease involving the ileum and/or the ascending colon and the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum a...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
ENTOCORT EC family patents
